Announced details
Endometriosis; gynecology
The company has licensed Synmosa Biopharma Corporation the development and sales rights for イセルティ (linzagolix) in Taiwan.
A Taiwanese listed company, established in 1980 and headquartered in Taiwan. Its chairman is Peter C.H. Lin. The company focuses on therapeutic areas including cardiovascular, respiratory, gynecology, urology, oncology and the central nervous system, and conducts research and development, manufacturing, contract manufacturing, sales and distribution of pharmaceuticals and health foods.
Taiwan Food and Drug Administration (TFDA)
Taiwan (Synmosa Biopharma Corporation headquarters)
Already reflected in the consolidated earnings forecast for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | イセルティ (generic name: linzagolix) |
| Counterparty | Synmosa Biopharma Corporation (ticker: TW.4114) |
| Counterparty overview | A Taiwanese listed company, established in 1980 and headquartered in Taiwan. Its chairman is Peter C.H. Lin. The company focuses on therapeutic areas including cardiovascular, respiratory, gynecology, urology, oncology and the central nervous system, and conducts research and development, manufacturing, contract manufacturing, sales and distribution of pharmaceuticals and health foods. |
| Relationship with the Company | The company has licensed Synmosa Biopharma Corporation the development and sales rights for イセルティ (linzagolix) in Taiwan. |
| Contract Date | November 2022 (development and sales rights in Taiwan licensed) |
| Launch date | As of 11 November 2026, an additional indication for endometriosis in Taiwan had been obtained. The launch date for the endometriosis indication is Not disclosed. |
| Applicable area | Endometriosis; gynecology |
| Awarding / certifying body | Taiwan Food and Drug Administration (TFDA) |
| Location | Taiwan (Synmosa Biopharma Corporation headquarters) |
| Impact on Business Performance | Already reflected in the consolidated earnings forecast for the fiscal year ending March 2027. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Taiwan Food and Drug Administration (TFDA) granted an additional indication for endometriosis. The company explained that the approval is expected to provide a new treatment option for patients with endometriosis in Taiwan.